TY  - GEN
AU  -  Gonzalez-Larriba, Jose Luis
AU  - Lazaro-Quintela, Martin
AU  - Cobo, Manuel
AU  - Domine, Manuel
AU  - Majem, Margarita
AU  - Garcia-Campelo, Rosario
PY  - 2017
DO  - 10.21037/tlcr.2017.10.03
SN  - 2218-6751
UR  - http://hdl.handle.net/10668/19479
T2  - Translational lung cancer research
AB  - One of the most important advances in the treatment of non-small cell lung cancer (NSCLC) has been the identification of molecular alterations vulnerable to targeted inhibition, such as mutations in the epidermal growth factor receptor (EGFR) gene....
LA  - en
PB  - AME Publishing Company
KW  - Epidermal growth factor receptor (EGFR)
KW  - tyrosine kinase inhibitor (TKI)
KW  - osimertinib
KW  - liquid biopsy
KW  - rebiopsy
KW  - Egfr t790m mutation
KW  - Acquired-resistance
KW  - Open-label
KW  - Phase-iii
KW  - 1st-line treatment
KW  - Met amplification
KW  - Carboplatin-paclitaxel
KW  - Gefitinib resistance
KW  - Gene-mutations
KW  - Nsclc patients
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Mutation, Missense
KW  - Drug Resistance, Neoplasm
KW  - Protein Kinase Inhibitors
KW  - Precision Medicine
KW  - Biopsy
KW  - Antineoplastic Agents
KW  - Treatment Outcome
TI  - Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis
TY  - review
VL  - 6
ER  -